Peptide Therapy and Your Health: What the Science Actually Shows
A calibrated, evidence-tiered map of the peptide landscape — written for people who want the honest answer, not the sales pitch.
Last updated: June 10, 2026 · By the MyOzempicDiet Team
Quick Answer
"Peptides" is not one category — it spans FDA-approved blockbusters like semaglutide and tirzepatide, prescription drugs like tesamorelin, supplement-shelf collagen, and a long tail of compounds sold as "research chemicals" with minimal human safety data. The honest evidence picture is tiered: a few peptides have very strong trial support; most do not. Anything you buy outside a licensed prescription pathway should be evaluated on the strength of a third-party Certificate of Analysis and the regulatory status of the molecule itself.
Key Takeaways
- GLP-1 peptides are the most rigorously studied therapeutic peptides in history.
- Most "wellness" peptides sit at Tier 2 or Tier 3 — the marketing far outruns the evidence.
- Animal data is not human data. Distinguishing them is the most important skill in this space.
- Third-party Certificates of Analysis are the minimum bar for vendor trust, not a guarantee of safety.
- If a peptide isn't FDA-approved for the use you want, your prescriber's judgment matters more than online testimonials.
What peptides actually are
Peptides are short chains of amino acids — usually between 2 and 50 — that act as biological signals. Insulin is a peptide. Oxytocin is a peptide. So is semaglutide. The fact that GLP-1 drugs themselves are peptides is the most useful credibility bridge into this space: the category is not exotic, but the rigor varies enormously between compounds.
The clinical question is never "are peptides good or bad." It's "what does the human evidence say about this specific peptide for this specific outcome at this specific dose." That's the lens this guide uses.
An evidence-tier framework
Every peptide in this guide is placed into one of three tiers:
Tier 1
FDA-approved with strong trial evidence.
Tier 2
Human trials exist but are limited, early, or off-label.
Tier 3
Primarily animal or preclinical data. Sold as 'research chemicals.' Not approved for human use.
The tier reflects evidence quality only — not your personal benefit/risk calculus. A Tier 1 drug can still be wrong for you. A Tier 3 compound is not necessarily harmful — it's that we don't have the human data to say either way.
Metabolic peptides
The class that put peptides on the mainstream map.
Semaglutide (Ozempic, Wegovy)
Tier 1What it is: GLP-1 receptor agonist for type 2 diabetes and weight management.
Evidence: Multiple Phase 3 RCTs (STEP, SUSTAIN, SELECT) showing 14–17% weight loss and cardiovascular risk reduction.
Known risks & unknowns: GI side effects, gallbladder events, contraindicated with personal/family history of MTC or MEN2.
Tirzepatide (Mounjaro, Zepbound)
Tier 1What it is: Dual GLP-1 / GIP receptor agonist.
Evidence: SURMOUNT trials showed up to 22.5% weight loss at the 15 mg dose over 72 weeks.
Known risks & unknowns: GI symptoms, same boxed warning as semaglutide; greater lean-mass decline in some analyses.
AOD-9604
Tier 3What it is: A synthetic fragment of human growth hormone marketed for fat loss.
Evidence: Did not meet primary endpoints in a 2007 Phase 2b weight-loss trial. Not FDA-approved.
Known risks & unknowns: Limited human safety data; widely sold as a research compound.
Growth-hormone-axis peptides
Compounds that signal the pituitary to release endogenous GH.
Tesamorelin (Egrifta)
Tier 1What it is: GHRH analog FDA-approved for HIV-associated lipodystrophy.
Evidence: RCTs show meaningful reductions in visceral adipose tissue. Studied off-label for general visceral fat.
Known risks & unknowns: Injection-site reactions, joint pain, transient glucose elevation.
CJC-1295 / Ipamorelin
Tier 2What it is: A GHRH analog plus a ghrelin-receptor agonist, often stacked.
Evidence: Small human studies show GH and IGF-1 elevation. No large body-composition or longevity RCTs.
Known risks & unknowns: Water retention, joint discomfort, elevated blood glucose, unknown long-term effects.
MK-677 (Ibutamoren)
Tier 2What it is: Oral ghrelin-receptor agonist (technically a small molecule, not a peptide).
Evidence: Human trials show GH and IGF-1 elevation; mixed results on body composition.
Known risks & unknowns: Significant water retention, insulin resistance, increased appetite.
Recovery and healing peptides
The most popular category in the wellness market — and the one with the largest evidence gap.
BPC-157
Tier 3What it is: A 15-amino-acid synthetic peptide based on a protein from gastric juice.
Evidence: Extensive animal studies show tissue and gut healing. Almost no controlled human trials. On the FDA 503A do-not-compound list.
Known risks & unknowns: Long-term human safety is unknown. Sold as a research chemical.
TB-500 (Thymosin beta-4 fragment)
Tier 3What it is: A synthetic fragment of thymosin beta-4, marketed for soft-tissue recovery.
Evidence: Animal studies and athlete anecdote. No published RCT support.
Known risks & unknowns: Unknown human pharmacokinetics, banned by WADA for athletes.
Skin, longevity, and immune peptides
Where supplement-shelf options meet experimental compounds.
Collagen peptides (oral)
Tier 1What it is: Hydrolyzed collagen sold as a dietary supplement.
Evidence: Meta-analyses suggest modest improvements in skin elasticity, hydration, and joint comfort.
Known risks & unknowns: Generally well tolerated; not regulated as a drug.
GHK-Cu (Copper peptide)
Tier 2What it is: Topical peptide used in cosmetics; injectable use is off-label.
Evidence: Reasonable topical-cosmetic evidence; injectable evidence limited.
Known risks & unknowns: Local irritation; injectable use lacks regulatory standing.
Thymosin Alpha-1
Tier 2What it is: An immune-modulating peptide approved in some countries (not the US) for hepatitis B and as an adjuvant.
Evidence: International trials in viral disease and oncology adjuvant settings.
Known risks & unknowns: Not FDA-approved in the US; injection-site reactions reported.
Epitalon
Tier 3What it is: A four-amino-acid peptide marketed for anti-aging and telomere extension.
Evidence: Small Russian studies, largely outside Western peer review.
Known risks & unknowns: Unknown long-term human safety profile.
Buyer Beware: the unregulated peptide market
Outside FDA-approved prescription pathways, the peptide market is largely self-regulated. That means quality, identity, and purity vary wildly. Before any purchase, insist on the following:
- A recent third-party Certificate of Analysis from an independent lab — not in-house testing.
- The COA should verify identity (it's the molecule on the label), purity (≥98%), and screen for endotoxins and heavy metals.
- Verify the issuing lab exists and the COA is not photoshopped from another product.
- US-based customer support and a real corporate address.
Red flags: vendors that ship "research only" peptides for human use, refuse to share COAs, list only a P.O. box, or make medical claims their compound is not approved to make.
Frequently Asked Questions
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Tier 3 compounds are not approved for human use. Consult a licensed healthcare provider before starting, stopping, or changing any medication or supplement.
A1C You L8tr! 👋
Get free health strategies to keep weight off after stopping blood sugar and A1C-altering medications. No fluff. No spam.
We respect your privacy. Unsubscribe anytime.